skip to Main Content

Nonengineered T-Cells May be ‘Clinically Meaningful’ for Pancreatic Cancer

Nonengineered T-Cells May be ‘Clinically Meaningful’ for Pancreatic Cancer
More than half of patients with pancreatic adenocarcinoma showed clinical responses when treated with an investigational multiantigen-specific T-cell therapy, according to the results of an ongoing phase 1 clinical trial presented at the ACCR’s Immune Cell Therapies for Cancer conference in San Francisco.

The nonengineered T-cell therapy used immune system cells called tumor-associated antigen (TAA)-specific cytotoxic T lymphocytes that simultaneously target the TAAs PRAME, SSX2, MAGEA4, NY-ESO-1 and Survivin. Read more . . . 


Back To Top